Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for NVO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 26.74%
March 31, 2026 50.15%
December 31, 2025 33.98%
September 30, 2025 26.68%
June 30, 2025 34.48%
March 31, 2025 37.18%
December 31, 2024 32.95%
September 30, 2024 38.28%
June 30, 2024 29.46%
March 31, 2024 38.88%
December 31, 2023 33.35%
September 30, 2023 38.27%
June 30, 2023 35.78%
March 31, 2023 37.13%
December 31, 2022 28.26%
September 30, 2022 31.61%
June 30, 2022 32.27%
March 31, 2022 33.81%
December 31, 2021 28.41%
September 30, 2021 34.02%
June 30, 2021 36.69%
March 31, 2021 37.34%
December 31, 2020 28.99%
September 30, 2020 33.30%
June 30, 2020 35.41%
Date Value
March 31, 2020 35.12%
December 31, 2019 26.89%
September 30, 2019 33.67%
June 30, 2019 31.94%
March 31, 2019 35.66%
December 31, 2018 28.58%
September 30, 2018 32.55%
June 30, 2018 37.74%
March 31, 2018 39.92%
December 31, 2017 29.48%
September 30, 2017 36.71%
June 30, 2017 34.75%
March 31, 2017 35.70%
December 31, 2016 29.42%
September 30, 2016 35.60%
June 30, 2016 36.30%
March 31, 2016 34.75%
December 31, 2015 28.60%
September 30, 2015 31.29%
June 30, 2015 30.83%
March 31, 2015 39.19%
December 31, 2014 26.56%
September 30, 2014 29.21%
June 30, 2014 32.34%
March 31, 2014 31.75%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 20.15%
Johnson & Johnson 21.86%
Eli Lilly & Co. 30.88%
Merck & Co., Inc. -8.06%
Novartis AG 22.61%